[
  {
    "ts": null,
    "headline": "The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut",
    "summary": "The reworked ACIP is making its debut. On Friday, the panelists weigh the suite of new Covid vaccines from Pfizer, Moderna and Novavax.",
    "url": "https://finnhub.io/api/news?id=a133c8e330265aaf231a3b7858680d34286f36a790f9e53a6d121e7e6c0f23b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758221356,
      "headline": "The Battle Over Covid Vaccines Hits A Fever Pitch As RFK-Picked Panel Makes Its Debut",
      "id": 136818428,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The reworked ACIP is making its debut. On Friday, the panelists weigh the suite of new Covid vaccines from Pfizer, Moderna and Novavax.",
      "url": "https://finnhub.io/api/news?id=a133c8e330265aaf231a3b7858680d34286f36a790f9e53a6d121e7e6c0f23b0"
    }
  },
  {
    "ts": null,
    "headline": "Formation Bio Expands Leadership Team With Top Biotech and Pharma Executives to Accelerate AI-Driven Drug Development",
    "summary": "Formation Bio, the AI-native pharmaceutical company revolutionizing drug development, today announced the appointment of four world-class leaders to its senior team: Louis Brenner, MD, as Chief Medical Officer; Daniel Neil, PhD, as Chief Technology Officer; and seasoned industry veterans Frank D'Amelio and Dashyant Dhanak, PhD, as Senior Advisors and members of our Investment Advisory Committee, alongside Mikael Dolsten MD, PhD. All of these leaders join the core group of executives at Formation",
    "url": "https://finnhub.io/api/news?id=551bfb8f5c4ca6f9c45d2e189dd2ca2d4cffc912552f2d62e0a1921ab0af9d1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758221220,
      "headline": "Formation Bio Expands Leadership Team With Top Biotech and Pharma Executives to Accelerate AI-Driven Drug Development",
      "id": 136801256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Formation Bio, the AI-native pharmaceutical company revolutionizing drug development, today announced the appointment of four world-class leaders to its senior team: Louis Brenner, MD, as Chief Medical Officer; Daniel Neil, PhD, as Chief Technology Officer; and seasoned industry veterans Frank D'Amelio and Dashyant Dhanak, PhD, as Senior Advisors and members of our Investment Advisory Committee, alongside Mikael Dolsten MD, PhD. All of these leaders join the core group of executives at Formation",
      "url": "https://finnhub.io/api/news?id=551bfb8f5c4ca6f9c45d2e189dd2ca2d4cffc912552f2d62e0a1921ab0af9d1b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Dividend Cushion Ratio Brings Yield Sustainability Into Question",
    "summary": "Pfizer Inc. faces significant uncertainty due to declining COVID-19 sales and potential policy changes. Learn more about PFE stock here.",
    "url": "https://finnhub.io/api/news?id=af394b63725cc311e6b1b70899addcd516d7d944b25a2fbfbe903a43d193c7d9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758211906,
      "headline": "Pfizer: Dividend Cushion Ratio Brings Yield Sustainability Into Question",
      "id": 136802088,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1379884472/image_1379884472.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer Inc. faces significant uncertainty due to declining COVID-19 sales and potential policy changes. Learn more about PFE stock here.",
      "url": "https://finnhub.io/api/news?id=af394b63725cc311e6b1b70899addcd516d7d944b25a2fbfbe903a43d193c7d9"
    }
  },
  {
    "ts": null,
    "headline": "Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?",
    "summary": "CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.",
    "url": "https://finnhub.io/api/news?id=43968007072c263b444bd50b81e084792619ee78fa491cc94b581c4b59c3848c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758210840,
      "headline": "Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification?",
      "id": 136799647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD's $300M Melinta buy adds seven therapies, easing reliance on DefenCath sales and bolstering growth in hospital-focused markets.",
      "url": "https://finnhub.io/api/news?id=43968007072c263b444bd50b81e084792619ee78fa491cc94b581c4b59c3848c"
    }
  },
  {
    "ts": null,
    "headline": "Atlassian to acquire developer productivity platform DX for $1 billion",
    "summary": "Enterprises have ramped up funding in AI capabilities as they compete to leverage the technology for innovation, operational efficiency, and competitive advantage.  In a move underscoring this trend, Atlassian earlier this month announced a $610 million deal to acquire The Browser Company, the maker of AI-powered Dia and Arc browsers.  Most of DX's enterprise customers such as Pfizer, Pinterest and Xero also use Atlassian to plan and track their work, CEO Mike Cannon Brookes said in a blog.",
    "url": "https://finnhub.io/api/news?id=ccdd6f05523d03de4fd9ec8bdd72e435c65f4a40bbf59362265348653cca7e47",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758204663,
      "headline": "Atlassian to acquire developer productivity platform DX for $1 billion",
      "id": 136799648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Enterprises have ramped up funding in AI capabilities as they compete to leverage the technology for innovation, operational efficiency, and competitive advantage.  In a move underscoring this trend, Atlassian earlier this month announced a $610 million deal to acquire The Browser Company, the maker of AI-powered Dia and Arc browsers.  Most of DX's enterprise customers such as Pfizer, Pinterest and Xero also use Atlassian to plan and track their work, CEO Mike Cannon Brookes said in a blog.",
      "url": "https://finnhub.io/api/news?id=ccdd6f05523d03de4fd9ec8bdd72e435c65f4a40bbf59362265348653cca7e47"
    }
  },
  {
    "ts": null,
    "headline": "Trump's battle with the pharma industry shows no signs of easing",
    "summary": "Drug makers are battling vaccine restrictions, pricing pressures, tariff threats, and Health Secretary Robert F. Kennedy, Jr.",
    "url": "https://finnhub.io/api/news?id=af29f041ab6c7a96e487926ac658bf0ffa99b00569a8adbba2ab9be746547173",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758189600,
      "headline": "Trump's battle with the pharma industry shows no signs of easing",
      "id": 136797749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Drug makers are battling vaccine restrictions, pricing pressures, tariff threats, and Health Secretary Robert F. Kennedy, Jr.",
      "url": "https://finnhub.io/api/news?id=af29f041ab6c7a96e487926ac658bf0ffa99b00569a8adbba2ab9be746547173"
    }
  },
  {
    "ts": null,
    "headline": "Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer",
    "summary": "COPENHAGEN, Denmark, September 18, 2025--Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer.",
    "url": "https://finnhub.io/api/news?id=ccd20fef3a49119f12e7b4efe535884ae2f2e648cb6d9c5c5cf53a40a1b122e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758189600,
      "headline": "Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer",
      "id": 136797748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "COPENHAGEN, Denmark, September 18, 2025--Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer.",
      "url": "https://finnhub.io/api/news?id=ccd20fef3a49119f12e7b4efe535884ae2f2e648cb6d9c5c5cf53a40a1b122e2"
    }
  },
  {
    "ts": null,
    "headline": "It Is Time To Buy Novo Nordisk Hand Over Fist",
    "summary": "Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.",
    "url": "https://finnhub.io/api/news?id=f26d7f9d18be7c9d325c14942cd167cc0a9c060fce57599bb030fe95427afe83",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758188162,
      "headline": "It Is Time To Buy Novo Nordisk Hand Over Fist",
      "id": 136798863,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2153927815/image_2153927815.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.",
      "url": "https://finnhub.io/api/news?id=f26d7f9d18be7c9d325c14942cd167cc0a9c060fce57599bb030fe95427afe83"
    }
  },
  {
    "ts": null,
    "headline": "1 Large-Cap Stock Worth Your Attention and 2 We Find Risky",
    "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
    "url": "https://finnhub.io/api/news?id=a2a9dd3b374c4dd36ef9168b1702c93b0b743be67118e643e65d95742185d9a1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758173571,
      "headline": "1 Large-Cap Stock Worth Your Attention and 2 We Find Risky",
      "id": 136797750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.",
      "url": "https://finnhub.io/api/news?id=a2a9dd3b374c4dd36ef9168b1702c93b0b743be67118e643e65d95742185d9a1"
    }
  }
]